Amgen 2012 Annual Report Download - page 34

Download and view the complete annual report

Please find page 34 of the 2012 Amgen annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 150

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123
  • 124
  • 125
  • 126
  • 127
  • 128
  • 129
  • 130
  • 131
  • 132
  • 133
  • 134
  • 135
  • 136
  • 137
  • 138
  • 139
  • 140
  • 141
  • 142
  • 143
  • 144
  • 145
  • 146
  • 147
  • 148
  • 149
  • 150

27
Molecule Disease/Condition
Phase 3 Programs
AMG 145 Hyperlipidemia
Aranesp® (darbepoetin alfa) Myelodysplastic syndromes
Brodalumab (AMG 827) Psoriasis
Prolia® (denosumab) Glucocorticoid-induced osteoporosis
Prolia® (denosumab) - EU Male osteoporosis
Rilotumumab Gastric cancer
Romosozumab (AMG 785) PMO
Sensipar®/Mimpara® (cinacalcet) Post renal transplant
Talimogene laherparepvec Melanoma
Trebananib (AMG 386) Ovarian cancer
Vectibix® (panitumumab) - U.S. First- and second-line colorectal cancer
XGEVA® (denosumab) Delay or prevention of bone metastases in breast cancer
XGEVA® (denosumab) - EU Delay or prevention of bone metastases in prostate cancer
XGEVA® (denosumab) Cancer-related bone damage (SREs) in patients with multiple myeloma
Phase 2 Programs
AMG 151 Type 2 diabetes
AMG 181 Inflammatory bowel disease
AMG 416 Secondary hyperparathyroidism in patients with CKD receiving dialysis
AMG 747 Schizophrenia
Blinatumomab (AMG 103) Acute lymphoblastic leukemia (ALL)
Blinatumomab Non-Hodgkin's Lymphoma (NHL)
Brodalumab Inflammatory diseases
Omecamtiv mecarbil Heart failure
Prolia® (denosumab) RA
Trebananib Various cancer types
Vectibix® (panitumumab) Squamous cell head and neck cancer
XGEVA® (denosumab) Giant cell tumor of the bone (GCTB)
XGEVA® (denosumab) Hypercalcemia of malignancy
Phase 1 Programs
AMG 110 Various cancer types
AMG 139 Inflammatory diseases
AMG 157 Asthma
AMG 167 Bone-related conditions
AMG 172 Various cancer types
AMG 208 Various cancer types
AMG 232 Various cancer types
AMG 319 Hematologic malignancies
AMG 334 Migraine
AMG 337 Various cancer types
AMG 357 Autoimmune diseases
AMG 557 Systemic lupus erythematosus
AMG 595 Glioblastoma
AMG 729 Autoimmune diseases
AMG 780 Various cancer types
AMG 811 Systemic lupus erythematosus
AMG 820 Various cancer types
AMG 876 Type 2 diabetes
AMG 900 Various cancer types